Tiagabine

DB00906ApprovedSmall moleculeAnti-epileptic Agent

Tiagabine is an antiepileptic used to treat partial seizures. Tiagabine is an anti-convulsive medication.

Mechanism: Though the exact mechanism by which Tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.
Curator reviewed
Primary indication: For the treatment of partial seizuresCurator reviewed · 1 structured indication
Formula / weight: C₂₀H₂₅NO₂S₂ · 375.548 g/mol (avg)
First approval: United States, 1997
Brand names: Gabitril

Resolves to

Compound

UNIIZ80I64HMNPCAS115103-54-3ChEMBLCHEMBL1027ChEBI9586PubChem60648KEGGC07503

Clinical / RWD

RxNorm31914ATCN03AG06PharmGKBPA451682

Structure

InChIKeyPBJUNZJWGZTSKL-MRXNPFEDSA-NSMILESCC1=C(SC=C1)C(=CCCN1CCC[C@H](C1)C(O)=O)C1=C(C)C=CS1

Targets

P30531SLC6A1

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

928Drug interactionsStructured to mechanism, not free text

12Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

39Marketed productsAcross 2 countries and 14 labellers

1ATC codeIncluding every combination product, plus 19 drug categories

14+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tiagabine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In